Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 123, Issue 12, Pages 5334-5341Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI70395
Keywords
-
Categories
Funding
- UNCF-Merck Graduate Fellowship [DA015546, T32-GM007280-34S1-NHLBI/NIGMS]
- NIDA Postdoctoral Training Program [DA007135]
- [DA023214]
- [DA030359]
- [DA006470]
Ask authors/readers for more resources
Negative affect is critical for conferring vulnerability to opiate addiction as reflected by the high comorbidity of opiate abuse with major depressive disorder (MDD). Rodent models implicate amygdala prodynorphin (Pdyn) as a mediator of negative affect; however, evidence of PDYN involvement in human negative affect is limited. Here, we found reduced PDYN mRNA expression in the postmortem human amygdala nucleus of the periamygdaloid. cortex (PAC) in both heroin abusers and MDD subjects. Similar to humans, rats that chronically self-administered heroin had reduced Pdyn mRNA expression in the PAC at a time point associated with a negative affective state. Using the in vivo functional imaging technology DREAMM (DREADD-assisted. metabolic mapping, where DREADD indicates designer receptors exclusively activated. by designer drugs), we found that selective inhibition of Pdyn-expressing neurons in the rat PAC increased metabolic activity in the extended amygdala, which is a key substrate of the extrahypothalamic brain stress system. In parallel, PAC-specific Pdyn inhibition provoked negative affect-related physiological and behavioral changes. Altogether, our translational study supports a functional role for impaired Pdyn in the PAC in opiate abuse through activation of the stress and negative affect neurocircuitry implicated in addiction vulnerability.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available